CNSY
Cerenome, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
3.07
▲ 0.07 (2.33%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
3.01
Prev close
3.00
Day high
3.12
Day low
2.97
Volume
106.18K
Market cap
—
P/E (TTM)
—
52W range
2.90 – 23.50
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-16.58%
-15.2%
1M
-18.78%
-22.5%
3M
-55.44%
-58.5%
6M
-56.14%
-67.2%
YTD
-75.92%
-88.2%
1Y
-74.42%
-94.4%
3Y
-94.86%
-169.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $8.38M | $10.58M | $9.69M | $9.70M | -20.8% |
| Selling, general & admin | $12.13M | $9.94M | $8.54M | $10.24M | +22.1% |
| Total operating expense | $15.30M | $14.70M | $13.32M | $19.71M | +4.1% |
| Operating income | -$15.30M | -$14.70M | -$13.32M | -$19.71M | -4.1% |
| Net interest income | -$3.49M | -$3.45M | $5.00K | -$564.00K | -1.2% |
| Pre-tax income | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -72.5% |
| Net income | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -72.5% |
| Net income to common | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -72.5% |
| Basic EPS | -7.25 | -48.75 | -106.00 | -288.75 | +85.1% |
| Diluted EPS | -7.25 | -58.50 | -106.00 | -288.75 | +87.6% |
| EBIT | -$18.78M | -$9.25M | -$12.92M | -$19.56M | -102.9% |
| EBITDA | -$18.33M | -$8.38M | -$12.29M | -$18.95M | -118.7% |
| Basic shares | 3.11M | 265.61K | 125.64K | 70.01K | +1,071.7% |
| Diluted shares | 3.11M | 308.03K | 125.64K | 70.01K | +910.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.26M | $76.00K | $8.55M | $18.12M | — | +5,500.0% |
| Cash & short-term investments | $8.61M | $3.61M | $8.55M | $18.12M | — | +138.8% |
| Total current assets | $15.17M | $5.26M | $9.83M | $21.82M | — | +188.5% |
| Property, plant & equipment | $327.00K | $521.00K | $1.11M | $1.57M | — | -37.2% |
| Goodwill & intangibles | $705.00K | $841.00K | $414.00K | $466.00K | — | -16.2% |
| Total assets | $16.32M | $6.63M | $11.39M | $23.87M | — | +146.1% |
| Total current liabilities | $12.31M | $15.55M | $10.73M | $11.85M | — | -20.8% |
| Current debt | $750.00K | $3.29M | $3.98M | $1.61M | — | -77.2% |
| Long-term debt | — | — | — | $3.79M | $5.00M | — |
| Total debt | $821.00K | $3.37M | $4.18M | $5.64M | — | -75.6% |
| Total liabilities | $12.33M | $15.58M | $12.74M | $17.42M | — | -20.9% |
| Retained earnings | -$515.87M | -$493.48M | -$480.50M | -$467.19M | — | -4.5% |
| Shareholder equity | $4.00M | -$8.95M | -$1.35M | $6.45M | — | +144.7% |
| Working capital | $2.86M | -$10.29M | -$893.00K | $9.96M | — | +127.7% |
| Net tangible assets | $3.29M | -$9.79M | -$1.76M | $5.98M | — | +133.6% |
| Shares issued | 5.56M | 246.19K | 180.91K | 89.60K | — | +2,157.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$22.39M | -$12.98M | -$13.32M | -$20.27M | -72.5% |
| Depreciation & amortisation | $445.00K | $872.00K | $628.00K | $619.00K | -49.0% |
| Stock-based compensation | $1.54M | $550.00K | $569.00K | $606.00K | +180.0% |
| Change in working capital | -$6.04M | $3.22M | -$1.12M | $5.60M | -287.5% |
| Operating cash flow | -$20.77M | -$10.55M | -$12.85M | -$12.97M | -96.8% |
| Capital expenditure | -$67.00K | -$691.00K | -$160.00K | -$759.00K | +90.3% |
| Investing cash flow | -$854.00K | -$4.11M | -$160.00K | -$759.00K | +79.2% |
| Share buybacks | $0 | -$374.00K | -$126.00K | $0 | +100.0% |
| Financing cash flow | $30.31M | $6.19M | $3.44M | $13.45M | +389.9% |
| Free cash flow | -$20.84M | -$11.24M | -$13.01M | -$13.73M | -85.3% |
| End cash position | $8.76M | $76.00K | $8.55M | $18.12M | +11,423.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $2.87M | $2.94M | $2.44M | $1.25M | $1.76M | -2.6% |
| Selling, general & admin | $5.28M | $4.17M | $3.44M | $1.68M | $2.84M | +26.7% |
| Total operating expense | $7.12M | $5.74M | $4.48M | $1.54M | $3.54M | +24.0% |
| Operating income | -$7.12M | -$5.74M | -$4.48M | -$1.54M | -$3.54M | -24.0% |
| Net interest income | $173.00K | $29.00K | $59.00K | $177.00K | -$3.76M | +496.6% |
| Pre-tax income | -$6.95M | -$5.71M | -$4.42M | $5.15M | -$17.40M | -21.6% |
| Net income | -$6.95M | -$5.71M | -$4.42M | $5.15M | -$17.40M | -21.6% |
| Net income to common | -$6.95M | -$5.71M | -$4.42M | $5.15M | -$17.40M | -21.6% |
| Basic EPS | -1.05 | — | -1.00 | 0.50 | -29.75 | — |
| Diluted EPS | -1.05 | — | -1.00 | 0.25 | -29.75 | — |
| EBIT | -$6.93M | -$2.65M | -$4.42M | $5.15M | -$16.85M | -161.3% |
| EBITDA | -$6.83M | -$2.56M | -$4.34M | $5.27M | -$16.71M | -166.9% |
| Basic shares | 6.65M | — | 4.30M | 1.94M | 582.67K | — |
| Diluted shares | 6.65M | — | 4.30M | 8.37M | 582.67K | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.02M | $4.26M | $13.29M | $2.23M | $9.87M | — | -29.0% |
| Cash & short-term investments | $15.11M | $8.61M | $16.60M | $6.88M | $9.87M | — | +75.5% |
| Total current assets | $18.03M | $15.17M | $17.59M | $9.21M | $10.87M | — | +18.8% |
| Property, plant & equipment | $1.07M | $327.00K | $293.00K | $318.00K | $362.00K | — | +227.2% |
| Goodwill & intangibles | $671.00K | $705.00K | $746.00K | $773.00K | $807.00K | — | -4.8% |
| Total assets | $19.92M | $16.32M | $18.67M | $10.35M | $12.06M | — | +22.0% |
| Total current liabilities | $7.96M | $12.31M | $13.62M | $7.32M | $10.56M | — | -35.4% |
| Current debt | $667.00K | $750.00K | — | — | — | $3.29M | -11.1% |
| Total debt | $725.00K | $821.00K | $21.00K | $30.00K | $40.00K | — | -11.7% |
| Total liabilities | $7.96M | $12.33M | $13.62M | $7.32M | $35.70M | — | -35.5% |
| Retained earnings | -$522.81M | -$515.87M | -$510.15M | -$505.73M | -$510.88M | — | -1.3% |
| Shareholder equity | $11.96M | $4.00M | $5.05M | $3.03M | -$23.64M | — | +199.3% |
| Working capital | $10.07M | $2.86M | $3.97M | $1.90M | $309.00K | — | +252.7% |
| Net tangible assets | $11.29M | $3.29M | $4.31M | $2.26M | -$24.45M | — | +243.1% |
| Shares issued | 6.87M | 5.56M | 5.27M | 3.70M | 690.32K | — | +23.7% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$6.95M | -$5.71M | -$4.42M | $5.15M | -$17.40M | — | -21.6% |
| Depreciation & amortisation | $96.00K | $92.00K | $86.00K | $121.00K | $146.00K | — | +4.3% |
| Stock-based compensation | $1.02M | $713.00K | $527.00K | $152.00K | $148.00K | — | +43.3% |
| Change in working capital | -$419.00K | -$1.36M | $1.26M | -$4.50M | -$1.44M | — | +69.2% |
| Operating cash flow | -$6.24M | -$6.26M | -$2.55M | -$5.80M | -$6.17M | — | +0.3% |
| Capital expenditure | -$818.00K | -$23.00K | -$34.00K | -$7.00K | -$3.00K | — | -3,456.5% |
| Investing cash flow | -$8.53M | -$1.08M | $1.30M | -$4.63M | $3.56M | — | -692.3% |
| Share buybacks | — | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $9.04M | $2.80M | $12.31M | $2.80M | $12.40M | — | +222.3% |
| Free cash flow | -$7.06M | -$6.28M | -$2.58M | -$5.80M | -$6.17M | — | -12.4% |
| End cash position | $3.02M | $8.76M | $13.29M | $2.23M | $9.87M | — | -65.5% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.43
-10.47% from price
SMA 20
3.60
-14.73% from price
SMA 50
3.94
-22.00% from price
SMA 100
4.81
-36.24% from price
SMA 200
7.57
-59.46% from price
EMA 12
3.39
-9.46% from price
EMA 26
3.65
-15.78% from price
EMA 50
4.05
-24.27% from price
RSI (14)
32.5
Neutral
MACD (12,26,9)
-0.25
Hist -0.05
ATR (14)
0.29
9.28% of price
Realised vol 30D
73.7%
Annualised
Bollinger upper
4.21
20, 2σ
Bollinger lower
2.99
20, 2σ
50 / 200 cross
Death
3.94 vs 7.57
Trend bias
Below 200
-59.46%
Risk profile
Beta vs SPY
1.72
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
73.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-86.9%
Peak to trough
Max drawdown 5Y
-99.6%
Peak to trough
ATR 14
0.29
9.28% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
GlobeNewswire · 3d ago
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
GlobeNewswire · 8d ago
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
GlobeNewswire · 10d ago
Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
GlobeNewswire · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.